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Abstract
Background: N-Methyl-D-aspartate receptors (NMDARs) play fundamental roles in basic brain functions such as
excitatory neurotransmission and learning and memory processes. Their function is largely regulated by factors
released by glial cells, including the coagonist D-serine. We investigated whether the activation of microglial
CX3CR1 induces the release of factors that modulate NMDAR functions.
Methods: We recorded the NMDAR component of the field excitatory postsynaptic potentials (NMDA-fEPSPs)
elicited in the CA1 stratum radiatum of mouse hippocampal slices by Shaffer collateral stimulation and evaluated
D-serine content in the extracellular medium of glial primary cultures by mass spectrometry analysis.
Results: We demonstrated that CX3CL1 increases NMDA-fEPSPs by a mechanism involving the activity of the
adenosine receptor type A2 (A2AR) and the release of the NMDAR coagonist D-serine. Specifically (1) the selective A2AR
blocker 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261) and the genetic
ablation of A2AR prevent CX3CL1 action while the A2AR agonist 5-(6-amino-2-(phenethylthio)-9H-purin-9-yl)-N-ethyl-3,
4-dihydroxytetrahydrofuran-2-carboxamide (VT7) mimics CX3CL1 effect, and (2) the selective blocking of the NMDAR
glycine (and D-serine) site by 5,7-dicholorokynurenic acid (DCKA), the enzymatic degradation of D-serine by D-amino
acid oxidase (DAAO) and the saturation of the coagonist site by D-serine, all block the CX3CL1 effect. In addition, mass
spectrometry analysis demonstrates that stimulation of microglia and astrocytes with CX3CL1 or VT7 increases D-serine
release in the extracellular medium.
Conclusions: CX3CL1 transiently potentiates NMDAR function though mechanisms involving A2AR activity and the
release of D-serine.
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Introduction
It is now widely accepted that, in addition to their well
established role in the immune system, chemokines and
their receptors play important roles in the central ner-
vous system (CNS), contributing to the homeostasis
of mature brain through neuroendocrine modulation,
neuromodulation and neuroglia communication (for re-
view see [1] and [2]).
Fractalkine (CX3CL1) is one of the chemokines most
abundantly expressed in the brain [3-5], especially by neu-
rons, whereas the only known CX3CL1 receptor, CX3CR1,
is expressed by microglial cells [5-7]. The CX3CR1/
CX3CL1 axis plays a major role in neuron/microglia cross-
talk and in neuroprotection under conditions of inflam-
mation/injury [5,8-10]. We have previously shown that
CX3CL1 reduces neuronal death induced by glutamate
(Glu) [11] through microglia-derived protective factors
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including adenosine [12,13] and in rodent models of
permanent ischemia, exogenous CX3CL1 administra-
tion is neuroprotective [14]. Moreover, at synapses
between Schaffer collaterals and pyramidal neurons in
the CA1 region of the hippocampus, CX3CL1 exerts a
neuromodulatory role inducing α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR)-
mediated excitatory synaptic depression and negatively
modulating long-term potentiation (LTP) mediated by
N-methyl-D-aspartate receptors (NMDAR) [15-17].
It is well established that NMDARs play an important
role in a variety of physiological and pathological pro-
cesses such as excitatory neurotransmission, synaptic
plasticity and excitotoxicity [18,19]. NMDAR function
is regulated by agents acting on a number of sites other
than the Glu binding site [20], such as glycine [21]
and D-serine that act with different affinities on the
same binding site [22]. A recent report describes that
D-serine preferentially acts on synaptic NMDARs,
whereas glycine acts on extrasynaptic NMDARs [23]. In
addition, D-serine is highly localized on glia in areas of
the brain particularly enriched in NMDARs [24], thus
suggesting that these cells are likely playing key roles in
regulating NMDAR-dependent processes including
synaptic transmission and synaptic plasticity. D-serine
is degraded by D-amino acid oxidase (DAAO) and is
mainly synthesized from L-serine by serine racemase
(SR) present primarily on astrocytes. Recent studies also
identified neurons and microglia as other important cel-
lular sources of serine in the brain [25-29] even thought
the role of neuronal and microglial D-serine remains to
be determined.
Microglia have long been characterized by their in-
nate immune activity in the nervous system, however
recent evidence has shed new light on microglia func-
tion. These cells are now recognized as full time part-
ners in neuronal function and the crosstalk between
neurons and microglia has been described in several
physiological and pathological conditions. Microglia
secrete a number of factors, including Glu, nitric oxide,
purines, trophic and anti-inflammatory substances [30],
but also soluble factors affecting NMDAR and AMPAR
such as glycine, cytokines, serine proteases and adeno-
sine [31-34]. We have previously shown that stimula-
tion of microglial cells with CX3CL1 induces the release
of adenosine, which mediates the reduction of AMPAR
function [13,15-17], but scarce information is available
on specific CX3CL1 effects on hippocampal NMDARs
[35] that are highly involved in synaptic plasticity
processes.
In the present work we demonstrate that CX3CL1
modulates NMDA-mediated synaptic transmission in
the hippocampal CA1 region, through the activity of the
A2AR and the release of D-serine from glia.
Methods
Animals
Experiments were performed in agreement with inter-
national guidelines on the ethical use of animals from the
European Communities Council Directive of 24 November
1986 (86/609 EEC). Hippocampal slices were routinely
obtained from 1-month-old C57BL/6. When specified, hip-
pocampal slices were obtained from gene modified
animals: (1) CX3CR1
GFP/GFP mice on the C57BL/6 back-
ground (from Charles River, Calco, Italy), that were gener-
ated by replacing the first 390 bp of the CX3CR1 gene with
the EGFP gene [6,36]; (2) A1R KO mice [37] and (3)
A3RKO mice [38] backcrossed at least ten times on a
C57BL/6 background; (4) A2 knockout mice [39] on a
BALB/cJ background (C;129S-Adora2atm1Jfc/J) and control
BALB/cJ wild-type mice (Charles River, Calco, Italy).
C57BL/6 and BALB/cJ wild-type mice showed similar
responses to CX3CL1 application (not shown).
Hippocampal slice preparation
Briefly, animals were decapitated after being anesthetized
with halothane. Whole brains were rapidly removed from
the skull and immersed for 10 minutes in ice-cold artificial
cerebrospinal fluid (ACSF) solution containing (1) for field
recording experiments (in mM): NaCl 125, KCl 4.4, CaCl2
2.5, MgSO4 1.5, NaHPO4 1, NaHCO3 26 and glucose 10;
(2) for patch clamp recordings (in mM): NaCl 125, KCl
2.5, NaH2PO4 1.25, NaHCO3 26, CaCl2 2, MgCl2 1, and
glucose 10. The ACSF was continuously oxygenated with
95% O2, 5% CO2 to maintain the proper pH (7.4).
Transverse (250 or 350 μm thick) slices were cut at 4°C
with a vibratome (DSK, Japan) and the slices were placed
in a chamber containing oxygenated ACSF. After their
preparation, slices were allowed to recover for 1 h before
recording.
For field recording experiments individual slices (350 μm
thick) were then transferred to the interface slice-recording
chamber (BSC1, Scientific System Design Inc., Mississauga,
Ontario, Canada) with a total fluid dead space of approxi-
mately 3 ml. Slices were maintained at 30 to 32°C and con-
stantly superfused at the rate of 2 ml/min. Solutions were
applied to the slices by a peristaltic pump.
For patch-clamp experiments, individual slices (250 μm
thick) were submerged in ACSF in the recording chamber
at room temperature. The ACSF was perfused at a rate of
approximately 1 ml/min.
In all experiments, unless otherwise specified, to isolate
the NMDAR component, a modified ACSF (M-ACSF)
containing low Mg2+ concentration (MgSO4 or MgCl2
were reduced to 0.2 mM) and the AMPA receptor blocker
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-
dione (NBQX; 10 mM) were perfused for at least
20 minutes.
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Field potential recording
Slices were visualized with a Wild M3B microscope
(Heerbrugg, Switzerland). At the beginning of each record-
ing, a concentric bipolar stimulating electrode (SNE-100X
50 mm long Elektronik-Harvard Apparatus GmbH, Crisel
Instruments, Rome Italy) was positioned in the stratum
radiatum for stimulation of Schaffer collateral pathway pro-
jections to CA1. An ACSF-filled glass micropipette (0.5 to
1 MΩ) was positioned 200 to 600 μm from the stimula-
ting electrode for recording the orthodromically-evoked
NMDAR component of field excitatory postsynaptic poten-
tials (NMDA-fEPSPs). Stimuli consisted of 100-μs-long
constant current square pulses, applied at 0.05 Hz. The in-
tensity of the stimulus was adjusted in each experiment to
evoke approximately 50% of the maximal field potential
amplitude without appreciable population spike contamin-
ation. Evoked responses were monitored online and stable
baseline responses were recorded for at least 10 minutes.
Only the slices that showed stable NMDA-fEPSP ampli-
tudes were included in the experiments. To analyze the
timecourse of the NMDA-fEPSPs slope, the recorded
NMDA-fEPSPs were routinely averaged over 1 minute
(N = 3). Experiments were performed in M-ACSF and aver-
aged NMDA-fEPSPs (last 5 minutes of treatment or wash-
out) were normalized to baseline values (5 minutes) prior
to treatment. In the text, n refers to the number of slices
analyzed/number of mice.
For the paired-pulse ratio (PPR) test, closely spaced
consecutive stimuli (50 ms interval) were used, and PPR
was calculated as the ratio between the NMDA-fEPSPs
amplitude evoked by the second stimulus (A2) over the
first (A1; A2/A1).
NMDA-fEPSPs were recorded and filtered (1 kHz) with
an Axopatch 200 A amplifier (Axon Instruments, CA,
USA) and digitized at 10 kHz with an A/D converter
(Digidata 1322A, Axon Instruments). Data were stored on
a computer using pClamp 9 software (Axon Instruments)
and analyzed offline with the Clampfit 9 program (Axon
Instruments).
Patch-clamp recordings
Neurons were visualized at 640 × with Nomarski optics
with an upright Zeiss (Thornwood, NY, USA) Axioscope
microscope. Patch-clamp recordings were obtained using
glass electrodes (3 to 4 MΩ) filled with the following
(in mM): CsMeSO4 135, CsCl 4, MgCl2 2, 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)
10, MgATP 2, NaGTP 0.3, (1,2-bis(o-aminophenoxy)eth-
ane-N,N,N',N'-tetraacetic acid (BAPTA) 5 (pH 7.3, with
CsOH). Neurons were clamped at −70 mV and perfused
with M-ACSF. NMDA currents in standard ACSF were
recorded at positive potential to remove Mg block (10
mV) using the following solution (in mM): CsCl 130,
MgCl2 2, HEPES 10, MgATP 2, NaGTP 0.3, BAPTA 5
(pH 7.3, with CsOH).
Membrane currents, recorded with a patch-clamp amp-
lifier (Axopatch 200A; Molecular Devices, Foster City,
CA, USA), were filtered at 2 kHz, digitized (10 kHz), and
acquired with pClamp 9 software (Molecular Devices,
Sunnyvale CA, USA). Excitatory postsynaptic currents
(EPSCs) were evoked in CA1 pyramidal neurons by elec-
trical stimulation with theta glass tubes pulled to a final
tip diameter of 10 to 20 μm and filled with external solu-
tion. Stimulating electrodes were placed in the stratum
radiatum to activate the Schaffer collateral pathway
projecting to CA1. NMDA-EPSCs were evoked by stimu-
lating at 5 to 50 V for 150 to 300 μs every 20 s. Recorded
EPSCs were routinely averaged over 1 minute (N = 3) to
analyze the timecourse of EPSC amplitude. Averaged
NMDA-EPSCs (last 5 minutes of treatment or washout)
were normalized to baseline values (5 minutes) prior to
treatment. Stable EPSCs were monitored for at least
10 minutes before applying CX3CL1 and successively
monitored during slice exposure to CX3CL1 (5 nM, a con-
centration close to the IC50 value for synaptic depression
of AMPA mediated responses and to the concentration
that inhibits NMDA-dependent LTP [15-17]. Data were
analyzed offline with Clampfit 9 (Axon Instruments).
Glia and neuron primary cultures
Primary cortical glial cells were prepared from 0 to
2-day-old mice. Cerebral cortices were chopped and
digested in 30 U/ml papain for 40 minutes at 37°C
followed by gentle trituration. The dissociated cells were
washed, suspended in Dulbecco’s modified Eagle medium
(DMEM) with 10% fetal bovine serum (FBS) (Invitrogen,
Life Technologies, Monza, Italy) and 2 mM L-glutamine
and plated at a density of 9 to 10 × 105 in 175 cm2 cell cul-
ture flasks. At confluence (11 days in vitro), glial cells were
plated (5.0 × 105 cells/cm2) on dishes coated with poly-L-
lysine (100 μg/ml) in DMEM supplemented with 10%
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin. To
detach and collect microglial cells, glial cells at confluence
(11 days in vitro) were shaken for 2 h at 37°C. These
procedures gave almost pure microglia (<2% astrocyte
contamination) and astrocytes cell population (4% to 6%
of microglia contamination), as verified by staining for
glial fibrillary acidic protein (GFAP) and isolectin IB4.
Cortical neuronal cultures were prepared from newborn
C57BL/6 mice (P0 to P1). Cerebral cortex were chopped
and digested in 20 U/ml papain for 40 minutes at 37°C.
Cells (13 × 104 cells/cm2) were plated on dishes coated
with poly-L-lysine (100 μg/mL) in basal medium Eagle
(BME) supplemented with 1 mM sodium pyruvate,
30 mM glucose, 0.1% Mito™ serum extender, 10% FBS,
100 U/mL penicillin, 0.1 mg/mL streptomycin and 10 mM
HEPES-NaOH (pH 7.4). After 4 h the medium was
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changed with Neurobasal medium supplemented with
1 mM glutamine, 0.1% Mito™ serum extender, 2.5% B27,
100 U/ml penicillin and 0.1 mg/mL streptomycin. After 2
days, AraC (5 μM) was added to avoid the growth of glial
cells. The percentage of neuronal cells obtained is 80% to
90%, as determined with β-tubulin III staining. Cultures
were used after 10 to 11 days.
Measurement of D-serine by liquid chromatography and
mass spectrometry (MS) analysis
Mixed glia, microglia and neuronal cultures at 11 days
old were pretreated in M-ACSF for 40 minutes and
stimulated for either 20 minutes, 2 h and 20 minutes
and 4 h with CX3CL1 10 nM or vehicle. After this time,
media were collected, centrifuged at 4°C for 10 minutes
at high speed, and the resulting supernatants were kept
to −20°C until use. Cells remaining in the dish were
analyzed for protein content with a BCA assay (Pierce,
Euroclone Pero, Italy).
Aliquots of the culture medium was derivatized
according to the method described by Berna and
Ackermann [40]. Briefly, samples (25 μl) were incubated
with 200 mM (pH 7.5) sodium bicarbonate solution and
10 μl of 1% Marfey’s reagent (w/v in acetone) at 60°C
for 1h.
Next, the samples were evaporated to dryness at 60°C
under a stream of nitrogen, and the dried residues were
reconstituted with 12.5% methanol in 15 mM ammo-
nium acetate. The samples were centrifuged at 600 g for
5 minutes and the supernatants diluted with 200 μl of
mobile phase. Injections of 20 μl were performed for
liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analysis. Marfey’s adducts of D standard
mixture were prepared by appropriate dilution of
the 100 μg/ml stock solution of D-serine in high-
performance liquid chromatography (HPLC)-grade
water and following the same derivatization procedure.
The LC-MS/MS system consisted of a PerkinElmer
200 Series binary pump and autosampler (PerkinElmer,
Norwalk, CT, USA) and an SCIEX API2000MS/MS
triple quadrupole mass spectrometer including a
Turbolon SprayW ionization source (Applied Biosystem-
MDS SCIEX, Thornhill, Ontario, Canada).
Chromatographic separation was performed on a
Synergi Polar RP column (150 × 2.0 mm, 4 μm), protected
by a guard column with identical packing material (4 ×
2.0 mm; Phenomenex, Torrance, CA, USA) The mobile
phase consisted of a linear gradient (30% to 70% with
respect to acetonitrile) formed by combination of 5 mM
ammonium formate buffer in water (pH 4.0, eluent A) and
acetonitrile (eluent B) at a flow rate of 0.2 ml/min.
D-Serine derivatives were detected using multiple reac-
tion monitoring (MRM) in negative ionization mode.
Selected ion masses of the protonated precursors and
fragmented ions (m/z) were 359.1 > 192. Chromatographic
peaks were integrated using Analyst™ software (version
1.4.1, SCIEX). The detection limits (LOD) and quantifica-
tion limits (LOQ) for D-serine were 1.71 ng/ml and
5.18 ng/ml respectively. The Marfey’s derivated isobaric
compounds L-Ser and D-Ser (2,4-dinitro-phenyl-5-L-
alanine amide- (DNPA-)L-Ser and DNPA-D-Ser) were
well resolved chromatographically as shown in Additional
file 1: Figure S1. An example of the blank samples (control
M-ACSF) is shown in Additional file 2: Figure S2, where
no signal corresponding to DNPA-L-Ser or DNPA-D-Ser
are present.
Statistical analysis
The values were reported as mean ± SEM. Unless other-
wise specified, data values refer to number of slices/
number of animals analyzed. Where appropriate, t tests
or one-way analysis of variance (ANOVA) were used.
Since in all experiments data passed the normality and
the equal variance tests, we performed parametric
ANOVA followed by Tukey or Holm-Sidak multiple-
comparison test (Sigma Plot, 11.0 software). If not speci-
fied, P values refer to ANOVA post hoc analyses.
Drugs
CX3CL1 (human, Peprotech Inc. Rocky Hill, NJ, USA), 7-
(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-
triazolo[1,5-c]pyrimidine (SCH58261, stock solution
10 mM in dimethylsulfoxide (DMSO)), triazoloquinazoline
(CGS15943, stock solution 5 mM in DMSO) and 1,
3-dipropyl-8-cyclopentylxanthine (DPCPX stock solution
5 mM in DMSO) by Tocris Bioscience, Bristol, UK. 3-
Propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-pro-
pyl-3-pyridine carboxylate (MRS1523, stock solution 10
mM), catalase, D-amino acid oxidase (DAAO), Marfey’s
reagent (Nα-(2,4-dinitro-5-fluophenyl)-L-alaninamide),
ammonium formate and Minocycline (stock solution 20
mM) from Sigma-Aldrich (Milan, Italy). NBQX (stock solu-
tion 20 mM), 5,7-dicholorokynurenic acid (DCKA, stock
solution 750 μM in 1 eq. NaOH) and D-serine (stock
solution 10 mM) by Ascent Scientific, Bristol, UK. 5-(6-
Amino-2-(phenethylthio)-9H-purin-9-yl)-N-ethyl-3,4 -dihy-
droxytetrahydrofuran-2-carboxamide (VT7, stock solution
10 mM in DMSO). Adenosine deaminase (ADA, Roche,
Germany). Acetonitrile, methanol, both gradient grades
were purchased from Merck (Darmstadt, Germany).
Ultrapure water was prepared using a Millu-Q system
(Millipore, MA, USA).
Drugs were dissolved in ACSF just before application.
Results
CX3CL1 increases hippocampal NMDA responses
To investigate whether CX3CL1 influences NMDA-
mediated synaptic transmission in hippocampal CA1
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region, we recorded the NMDAR component of the fEPSPs
(NMDA-fEPSPs) elicited in the CA1 stratum radiatum of
mouse hippocampal slices by electrical stimulation of the
Schaffer collateral (at 0.05 Hz). To isolate the NMDA com-
ponent of the fEPSPs slices were treated with the AMPA
receptor blocker NBQX (10 μM) and with low (0.2 mM)
magnesium [41]. In control slices, synaptic activity was
stable for at least 30 minutes (not shown). We challenged
the slices with CX3CL1 at concentrations of 5 nM. In the
majority of the experiments (25 out of 35 slices tested, 28
mice; Figure 1A) bath application of CX3CL1 for 20 mi-
nutes induced a short-term potentiation (STP) of synaptic
transmission. The potentiation of the NMDA-fEPSPs slope
developed within 5 minutes of CX3CL1 application was
1.22 ± 0.03 of baseline (from 1.92 to 1.01 in different exper-
iments, measured here and thereafter after 20 minutes of
treatment, P <0.05) and was followed by partial recovery
(to 1.15 ± 0.01 of baseline, P <0.05, measured here and
thereafter at 20 minutes of CX3CL1 withdrawal) with a few
exceptions where full recovery was observed. To exclude
the possibility that CX3CL1 treatment induces a change in
presynaptic cell excitability, such as the recruitment of
more presynaptic fibers by the same stimulus, changes
in the amplitude of extracellular fiber volley (an index
of presynaptic excitation) were monitored by recording
evoked fEPSPs during CX3CL1 application. As shown in
Additional file 3: Figure S3A, in a subset of slices where
the potentiating effect of CX3CL1 was maximal (41.68 ±
0.05 of baseline, n = 5, P <0.05) the amplitude of the
afferent volley did not change after treatment with
CX3CL1 (P = 0.45, paired t test).
Patch-clamp experiments were carried out to measure
CX3CL1-mediated modulation of NMDA current at the
single cell level. Whole-cell recordings of NMDA-
EPSCs were performed in CA1 pyramidal neurons in
acute slices while repeatedly stimulating Schaffer collat-
eral axons. CX3CL1 treatment caused an increase in
NMDA-EPSC peak amplitude (to 1.25 ± 0.03 P < 0.05
vs baseline) that recovered upon withdrawal (to 1.06 ±
0.04 P >0.05 vs baseline, Figure 1B, five slices/five mice).
These results confirmed the CX3CL1-mediated potenti-
ation of NMDA responses also at the single cell level.
Paired pulse facilitation (PPF) ratio is not altered by
CX3CL1 application
To analyze if CX3CL1 potentiates NMDA-fEPSPs by
altering presynaptic glutamate release, we performed
studies of short-term plasticity, that is, paired-pulse ratio
(PPR) measurements. The PPR, which is the ratio of the
amplitude of the second response vs the first, depends
on the probability of vesicular release at synapse and its
variation is generally associated with changes in trans-
mitter release probability [42].
To evaluate PPR values we stimulated Schaffer collateral
pathway projections to CA1 at 50 ms intervals. As shown
in Additional file 3: Figure S3B, PPR was 1.53 ± 0.017 and
1.54 ± 0.026 before and after 20 min of CX3CL1 treatment
(6 slices/4 mice, P = 0.74, paired t test), respectively.
Presynaptic release of Glu can be affected by removal of
Mg2+ from the external solution, changing the competi-
tion between Mg2+ and Ca2+ at terminal endings and al-
tering PPR mechanisms [43]. To investigate this possibility
we repeated the PPR measurements in whole-cell experi-
ments where the NMDA current were isolated by depolar-
izing the cell in a standard ACSF medium. As shown in
Additional file 3: Figure S3C, the PPR measured in this
Figure 1 CX3CL1 produces transient N-methyl-D-aspartate receptor (NMDAR) potentiation in CA1 pyramidal neurons (STP). Horizontal
bar, CX3CL1 application (5 nM). (A) CX3CL1 increases NMDA-field excitatory postsynaptic potentials (fEPSPs) slope. Top: representative average
traces of NMDA-fEPSPs recorded in control (1 minute before application), after 20 minutes of CX3CL1 treatment and at 20 minutes of withdrawal,
as indicated. Vertical scale bar: 0.2 mV, horizontal scale bar: 20 ms. Bottom: average timecourse of CX3CL1-induced increase of the NMDA-fEPSPs
slope in mouse hippocampal slices (n = 35/28). Here and thereafter each point represents the average of three responses evoked every 20 s, as
detailed in Methods. (B) CX3CL1 increases the amplitude of evoked excitatory postsynaptic currents (EPSCs). Top: sample traces of EPSCs (average
of three events over 1 minute) recorded before, after 20 minutes of chemokine application, and 20 minutes after washout, as indicated. Vertical
scale bar: 20 pA, horizontal scale bar: 20 ms. Bottom: average timecourse of the current peak amplitude. Circles represent averages of three
responses evoked every 20 s in five different slices (five mice).
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condition was 1.43 ± 0.08 and 1.44 ± 0.09 before and
after 20 minutes of CX3CL1 treatment, (5 slices/5 mice,
P = 0.81, paired t test). These data indicated that under
our experimental conditions, CX3CL1 treatment did not
cause obvious changes in presynaptic release probability,
confirming the postsynaptic nature of the potentiation of
NMDA-fEPSPs, in line with our previous findings [15,44].
CX3CL1-mediated effects require the presence of CX3CR1
on microglial cells
To demonstrate that the effects of CX3CL1 were indeed
mediated by CX3CR1, experiments were performed on
CX3CR1
GFP/GFP mice where the murine CX3CR1 gene was
replaced with the cDNA encoding EGFP (Jung et al. [6]).
Application of CX3CL1 for 20 minutes to CX3CR1
GFP/GFP
hippocampal slices (Figure 2A, seven slices/three mice)
failed to induce any obvious basal NMDA-fEPSPs slope
change (P > 0.05). These findings clearly show that
CX3CL1-induced effects on NMDA-fEPSPs were medi-
ated through CX3CR1 activation.
Since CX3CR1 is expressed on microglial cells [5,6],
we wondered whether microglial activation was required
for CX3CL1-mediated STP of NMDA-fEPSPs. For this
purpose we treated hippocampal slices with a broad-
spectrum tetracycline antibiotic, minocycline, known to
inhibits microglial activation [45-47].
As shown in Figure 2B, in the presence of minocycline
(20 μM, 1 h preincubation), the application of CX3CL1
did not significantly affect the NMDA-fEPSPs (P > 0.5,
eight slices/two mice), demonstrating a microglia-driven
chemokine effect.
CX3CL1-mediated NMDAR potentiation is mediated by
ARs
We have previously shown that CX3CL1 treatment induces
the release of adenosine from microglia [12] and that
CX3CL1-mediated modulation of synaptic transmission
and plasticity involves AR activity [17,48]. In addition, it is
known that AR activity in the hippocampus modulates
NMDA receptor functioning [49]. For all these reasons we
investigated whether CX3CL1 effects on NMDARs require
AR activity. We first treated hippocampal slices with the
broad-spectrum AR antagonist CGS15943. The applica-
tions of CGS15943 (1 μM) abolished CX3CL1-mediated
STP of NMDA-fEPSPs (Figure 3A, P > 0.05 vs baseline,
nine slices/four mice) indicating that the activity of ARs is
indeed involved in CX3CL1 effects.
To disclose the specific role of distinct AR subtypes,
we performed additional experiments with selective A1R,
A2AR and A3R antagonists (Figure 3B-D).
Specifically, the A1R antagonist DPCPX (25 nM) failed
to prevent CX3CL1-mediated modulation of NMDAR, as
the NMDA-fEPSPs slope increased during CX3CL1 treat-
ment (to 1.25 ± 0.01, P < 0.05 vs baseline, P > 0.05 vs
CX3CL1 alone) and remained high upon withdrawal (to
1.25 ± 0.04 P < 0.05 vs baseline, Figure 3B, nine slices/five
mice). Similarly, the specific A3R antagonist MRS1523
(100 nM) was unable to affect the action of CX3CL1 that
elicited a significant increase in NMDA-fEPSPs slope (to
1.23 ± 0.01, P < 0.05 vs baseline, P > 0.05 vs CX3CL1
alone) partially recovering upon withdrawal (1.12 ± 0.01,
P < 0.05 vs baseline, Figure 3C, ten slices/five mice).
Conversely, when slices were treated with the selective
A2AR antagonist SCH58261 (10 nM), CX3CL1 was unable
to affect NMDA-fEPSPs slope (Figure 3D, P > 0.05 vs
baseline P < 0.01 vs CX3CL1 alone, six slices/three mice),
indicating that A2AR activity is associated with CX3CL1
effects on NMDAR-dependent basal transmission.
The role of ARs in CX3CL1 effects was further inves-
tigated by means of mice selectively lacking AR sub-
types. As shown in Figure 4A application of CX3CL1 in
A1R
−/− mice increased NMDA-fEPSPs slope (to 1.14 ±
0.01, P < 0.05 vs baseline) that partially recovered after
washout (to 1.04 ±0.02, P > 0.05 vs baseline, ten slices/
Figure 2 CX3CR1 and microglia activation are required for CX3CL1 effects. Points represent mean ± SEM of the N-methyl-D-aspartate
receptor component of field excitatory postsynaptic potential (NMDA-fEPSP) slopes. Average timecourse of changes in NMDA-fEPSPs recorded in
hippocampal slices. Horizontal bar, CX3CL1 application (5 nM). (A) CX3CL1-mediated effects required the presence of CX3CR1 (n = 7/3). (B)
Microglia activation is necessary for CX3CL1 action. Slices pretreated for 1 h with minocycline (last 10 minutes in the graph) and then
continuously superperfused. Cotreatment with CX3CL1 did not increase NMDA-fEPSPs (n = 8/2).
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three mice). Similar results were obtained in A3R
−/− mice,
where CX3CL1 elicited a significant increase of NMDA-
fEPSPs slope (to 1.11 ± 0.01, P < 0.05 vs baseline) that
recovered upon withdrawal (to 1.02 ± 0.01, P > 0.05 to
baseline, Figure 4B, ten slices/two mice). Interestingly, in
accordance with pharmacological data, in A2AR deficient
mice (A2AR
−/−) CX3CL1 was unable to affect NMDA-
fEPSPs. (P > 0.05, vs baseline, 11 slices/3 mice, Figure 4C),
thus pointing to an essential role of A2AR activity in the
CX3CL1 effect. To further support this observation, we
tested whether a selective A2AR agonist, VT7 (50 nM), was
able to mimic CX3CL1 effect. The results in Figure 5A
demonstrate that in the presence of adenosine deami-
nase (ADA, 1 U/ml), which removes ambient adenosine
[50], VT7 induced an increase of NMDA-fEPSPs slope
(to 1.18 ± 0.01, P < 0.05 vs baseline, nine slices/two
mice) that did not recover after washout (to 1.15 ± 0.01,
P < 0.05 vs baseline).
Considered together, our findings indicate that the
influence of CX3CL1 on NMDARs is mediated by the
A2AR activity.
D-serine is involved in CX3CL1-dependent modulation of
NMDARs
Recent evidence indicates that D-serine serves as indis-
pensable cofactor at the glycine binding site of NMDARs
representing a new and important glia-derived neuromo-
dulatory factor [51]. In fact, in glial cells, D-serine is
synthesized and metabolized endogenously by the
enzymes serine racemase (SR) [52] and D-amino acid
oxidase (DAAO) [53], respectively.
To investigate whether D-serine is involved in
CX3CL1-mediated modulation of NMDARs, we first
treated the slices with the selective NMDAR glycine-site
antagonist 5,7-dichlorokynurenic acid (DCKA) at a con-
centration (750 nM) known to reduce NMDA responses
Figure 3 Adenosine receptors (ARs) are involved in CX3CL1-mediated short-term potentiation (STP) of N-methyl-D-aspartate receptor
(NMDAR). (A-D) Slices pretreated for 20 minutes with AR antagonists (last 10 minutes in the graph) and then continuously treated. Inset on top:
representative NMDAR component of field excitatory postsynaptic potential (NMDA-fEPSP) traces recorded in control condition, in the presence
of CX3CL1 and during washout, as indicated (same time points as Figure 1). Vertical scale bar: 0.5 mV, horizontal scale bar: 20 ms. Graphs
represent the average timecourse of CX3CL1 effects on NMDA-fEPSPs in the presence of AR antagonists. Points: mean ± SEM. Horizontal bar,
CX3CL1 application (5 nM). (A) Slices superfusion with the non-selective AR antagonist, triazoloquinazoline (CGS15943) (25 nM) prevented CX3CL1
action (n = 9/4). (B) CX3CL1 application in the presence of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (25 nM), was effective (n = 9/5). (C) CX3CL1
application in the presence of 3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-propyl-3-pyridine carboxylate (MRS1523) (100 nM) induced a
significant increase of NMDA-fEPSPs (n = 10/5). (D) 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH58261)
(10 nM) prevented CX3CL1 action (n = 6/3).
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by around 25% [54] and able to prevent D-serine medi-
ated increase of NMDA-fEPSPs slope (n = 7, data not
shown). At this concentration, DCKA abolished CX3CL1
effects on NMDA-fEPSPs (P > 0.05 vs baseline, eight
slices/four mice, Figure 6A).
To disclose a possible D-serine versus glycine coagonist
requirement, we treated the slices with DAAO (0.1 U/ml).
Excess catalase (300 U/ml) was added in the solution
in order to avoid the possibility of hydrogen peroxide
Figure 4 The absence of adenosine receptor type A2 (A2AR)
prevents CX3CL1 action. Graphs represent the average timecourse of
CX3CL1 effects on N-methyl-D-aspartate receptor component of field
excitatory postsynaptic potentials (NMDA-fEPSPs). Points: mean ± SEM.
Horizontal bar, CX3CL1 application (5 nM). (A) In A1R
−/− mice, application
of CX3CL1 enhanced NMDA-fEPSPs (n = 10/3). (B) The absence of A3R
did not interfere with CX3CL1 action (n = 10/2). (C) In A2AR
−/− mice,
CX3CL1 was ineffective (n = 11/3).
Figure 5 5-(6-Amino-2-(phenethylthio)-9H-purin-9-yl)-N-ethyl-3,
4-dihydroxytetrahydrofuran-2-carboxamide (VT7) increases
hippocampal N-methyl-D-aspartate receptor component of
field excitatory postsynaptic potentials (NMDA-fEPSPs) and its
action depends on D-serine. Averaged timecourse of changes in
NMDA-fEPSPs recorded in hippocampal slices. Points: mean ± SEM.
Horizontal bar, VT7 application (50 nM). Inset on top: representative
NMDA-fEPSP traces recorded in control conditions, in the presence of VT7
and during washout, as indicated (same time points as Figure 1). Vertical
scale bar: 0.1 mV, horizontal scale bar: 20 ms. Slices treated with adenosine
deaminase (ADA), 1 U/ml. (A) Application of VT7 enhances NMDA-fEPSP
slopes (n = 9/2). (B) Blocking of the NMDAR D-serine site completely
prevents the VT7 effect on NMDA-fEPSP slopes. Slices pretreated with 5,7-
dicholorokynurenic acid (DCKA) (750 nM) for 20 minutes (last 10 minutes
in the graph) before VT7 application and then continuously treated
(n = 11/3). (C) Degradation of D-serine block VT7-mediated NMDA
modulation. Slices pretreated for 1 h and then continuously superperfused
with D-amino acid oxidase (DAAO) (0.1 U/ml) and catalase (300 U/ml).
Cotreatment with VT7 did not increase NMDA-fEPSPs slope (n = 7/3).
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production from the enzymatic degradation of D-serine by
DAAO. Under this condition, DAAO completely
prevented CX3CL1 action (P > 0.05 vs baseline, ten slices/
four mice, Figure 6B), indicating that D-serine is neces-
sary. To further confirm the involvement of D-serine in
the modulation of NMDARs by CX3CL1, we applied ex-
ogenous D-serine (10 μM, six slices/four mice, Figure 6C)
to hippocampal slices. As shown in Figure 6C, D-serine
produced an increase in NMDA-fEPSPs slope reaching a
plateaux effect within 20 minutes (up to 64.4 ± 0.01 after
40 minutes treatment, P < 0.05 vs baseline). Subsequent
coapplication of CX3CL1 failed to further increase
NMDA-fEPSPs slope (P > 0.05 vs D-serine alone), indicat-
ing that saturation of the glycine site by D-serine interferes
with chemokine action.
Since we have demonstrated that the CX3CL1 effect is
prevented by hampering both D-serine and A2AR functions,
we investigated whether the two pathways share some
common mechanisms of action. For this reason we applied
the A2AR agonist VT7 (in the presence of ADA, 1 U/ml)
while partially blocking the NMDAR D-serine site by
DCKA. In this condition, VT7 failed to increase NMDA-
fEPSPs slope (P > 0.05 vs baseline, Figure 5B, 11 slices/
3 mice). In addition, slices pretreatment with DAAO
(0.1 U/ml, in the presence of catalase, 300 U/ml, and ADA,
1 U/ml) inhibits VT7 action (>0.05 vs baseline, Figure 5C,
seven slices/three mice). Taken together this evidence sug-
gests that NMDAR modulation mediated by A2AR requires
D-serine.
CX3CL1 and VT7 stimulate the release of D-serine from
glia cells
To further investigate the possible source of D-serine in
CX3CL1-induced NMDAR modulation, we measured
D-serine levels in glia-conditioned medium. The control
medium (M-ACSF) did not contain D-serine, as it is
shown in Additional file 2: Figure S2.
Primary cortical glial cells and isolated microglial cell
populations were stimulated with CX3CL1 (10 nM) for
different times (20 minutes, 2 h and 20 minutes or 4 h).
After stimulation, mass spectrometry was performed on
media samples.
Treatment of both primary purified microglia and mixed
glia with CX3CL1 resulted in a large increase in D-serine in
the medium (Figure 7). In particular, in microglial cells
CX3CL1 induced a significant increase in D-serine release
at all the incubation times considered (1.53 ± 0.08 after
20 minutes, 1.26 ± 0.07 after 2 h and 20 minutes and
2.63 ± 0.80 after 4 h, P < 0.05 in all cases vs untreated,
n = 8, Figure 7A). Similarly, CX3CL1 treatment augmented
D-serine level in the medium of mixed glia (1.76 ± 0.19
after 20 minutes, 1.66 ± 0.11 after 2 h and 20 minutes and
1.52 ± 0.24 after 4 h, P < 0.05 in all cases vs untreated,
n = 8, Figure 7B).
We then tested whether also the A2AR agonist VT7 was
able to modulate the release of D-serine from glia. For this
purpose we stimulated the cells with VT7 (50 nM) in the
Figure 6 D-Serine is involved in CX3CL1 action. Graphs represent
the average timecourse of N-methyl-D-aspartate receptor component
of field excitatory postsynaptic potentials (NMDA-fEPSPs). Points: mean
± SEM. Black horizontal bar, CX3CL1 application (5 nM). (A) Blocking of
NMDAR glycine site prevented CX3CL1 effects. Slices pretreated with
5,7-dicholorokynurenic acid (DCKA) (750 nM) for 20 minutes before
CX3CL1 applications (last 10 minutes in the graph) and then
continuously treated. Note the absence of CX3CL1 effect (n = 8/4). (B)
Enzymatic degradation of D-serine abolished CX3CL1-mediated
NMDAR modulation. Slices pretreated for 1 h and then continuously
superperfused with D-amino acid oxidase (DAAO) (0.1 U/ml) and
catalase (300 U/ml). Cotreatment with CX3CL1 did not increase
NMDA-fEPSP slopes (n = 10/4). (C) Saturation of NMDAR glycine site by
D-serine prevented CX3CL1 action. Treatment with D-serine (10 μM,
open bar as indicated) increased basal NMDA-fEPSPs slope and
occluded CX3CL1 effect (n = 6/4).
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continuous presence of adenosine deaminase (ADA,
1 U/ml). As for CX3CL1, the A2AR agonist was able to
induce an increment in the basal level of D-serine. Specific-
ally, VT7 treatment produced an increase in D-serine re-
lease in both primary purified microglia (up to: 1.28 ± 0.13
after 20 minutes, 1.38 ± 0.10 after 2 h and 20 minutes and
1.60 ± 0.30 after 4 h, P < 0.05 in all cases vs untreated,
n = 9, Figure 7C) and mixed glia medium (up to: 1.53 ±
0.10 after 20 minutes, 1.37 ± 0.06 after 2 h and 20 minutes
and 1.47 ± 0.12 after 4 h, P < 0.05 in all cases vs untreated,
n = 12, Figure 7D), respectively. Interestingly, the control
basal level of D-serine in purified microglia medium was
unchanged at different time points, whereas in mixed glia it
accumulates upon time, and it had similar values (at 20
minutes, both in M-ACSF or M-ACSF plus ADA, P >0.05
for all cases). In addition, the level of basal D-serine
released by mixed glia or microglia was in the order of
10 fmol/cell, accordingly to previously reported values [25].
We further tested the ability of VT7 to induce the release
of D-serine form neurons in the presence of ADA. During
treatment, no variation in the basal level of D-serine was
observed, at all time points considered (P > 0.05 vs
untreated, n = 12). Notably, the basal level of D-serine
released by neurons was much lower compared to glia (at
20 minutes: 37.24 ± 7.02 ng/mg of protein, n = 12).
Discussion
The main finding of the present study is that NMDAR
function, in CA1 hippocampal region, is potentiated by
CX3CL1 application. The activation of the glial A2AR and
the release of the NMDAR coagonist D-serine are
likely major causative factors for the observed NMDA
Figure 7 CX3CL1 and 5-(6-amino-2-(phenethylthio)-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (VT7) induce
extracellular accumulation of D-serine. Mass spectroscopy analysis of D-serine levels in primary purified microglia or mixed glia culture
medium (A,B). Cells were stimulated with CX3CL1 (10 nM) or vehicle and after 20 minutes, 2 h and 20 minutes or 4 h (as indicated) medium was
collected and analyzed for D-serine content. Results are expressed as ng extracellular D-serine accumulated per mg of cellular proteins and are
the mean ± SEM of eight independent experiments. (A) Shows purified microglia, (B) shows mixed glia culture medium. (C,D) Cells stimulated
with VT7 (50 nM) plus adenosine deaminase (ADA, 1 U/ml) or vehicle (ADA, 1 U/ml) and samples collected as in (A,B). (C) Shows purified
microglia, (D) shows mixed glia culture medium. Results are the mean ± SEM of nine experiments (C) or 12 experiments (D). White square,
vehicle; black square treatment, as indicated. *P <0.05.
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potentiation. Interestingly this effect is postsynaptic in
nature, depends on microglia and requires the presence of
CX3CR1. Specifically, the parameter related to changes in
the probability of vesicular release at the synapse, such as
PPR, was not affected by CX3CL1, indicating that the
chemokine did not potentiate NMDA-fEPSPs by altering
presynaptic glutamate release (see also [15,44]). In addition,
the use of genetically modified mice lacking CX3CR1 or
inhibiting microglia function by minocycline treatment
prevented CX3CL1-mediated potentiation of NMDAR
function.
A2AR activity is involved in CX3CL1 effect
It is established that adenosine acts as neuromodulator of
NMDAR function; in particular A2ARs exert a facilitatory
role on NMDARs [55,56]. Nevertheless, the consequences
of A2AR activation on synaptic transmission in physiological
conditions of adenosine release remained elusive. Since the
ambient level of adenosine is sufficient to activate inhibitory
A1R but not facilitatory A2AR, possibly due to differences in
affinity [57], it is believed that specific stimulation such as
high-frequency bursts is needed to increase the level of
adenosine to values able to activate A2AR [58]. Indeed, we
have previously demonstrated that stimulation of microglial
cells by CX3CL1 induces an increase in extracellular level
of adenosine [12].
Here, we reported that CX3CL1-mediated activation of
A2AR influences the NMDA-mediated component of exci-
tatory synaptic transmission. In particular, the specific
A2AR blocker SCH58261, as well as the genetic ablation of
A2AR, prevented the short-term potentiation of NMDA
fEPSPs induced by CX3CL1. In addition, the specific A2AR
agonist VT7 was able to mimic CX3CL1 effect, producing a
similar potentiation of NMDA-fEPSPs.
D-serine is essential for CX3CL1-mediated potentiation of
NMDA-fEPSPs
It is well established that D-serine act as an essential
coagonist of NMDAR. The production of D-serine in the
mammalian brain results from the activity of SR, an en-
zyme that converts L-serine into D-serine [59]. Astrocytes
synthesize and release D-serine [25], for instance following
activation of AMPARs by glutamate released from nerve
terminals [24,60]. In contrast, scarce information is avail-
able on microglia derived D-serine. It has been reported
that microglia express serine racemase [27-29] and release
D-serine after activation with amyloid β-peptide [25].
We demonstrated that D-serine is involved in CX3CL1-
mediated potentiation of NMDA-fEPSPs because its action
is prevented by: (i) the selective NMDAR antagonist
of the glycine (and D-serine)-binding site DCKA, (ii) the
enzymatic degradation of D-serine by DAAO, and (iii) the
saturation of the coagonist site by D-serine.
In addition, mass spectrometry analysis revealed that
treatment of primary mixed glial cells and purified micro-
glial population with CX3CL1 induces a significant increase
of D-serine release in the extracellular medium. The glial
population used for these studies was derived from cerebral
cortices and we are aware that microglial phenotypes differ
across brain regions and ages [61,62], so that results from
these preparation cannot be directly transferred to hippo-
campal glial cells; nevertheless these data strongly support a
direct role of CX3CL1 in controlling D-serine release from
glia, that need further investigation, and clearly demon-
strate a basal release of D-serine from microglial cells that
can be further increased by CX3CL1 treatment.
Overall, the evidence suggests that both A2AR activity
and D-serine release are needed for CX3CL1-mediated po-
tentiation of NMDA-fEPSPs. Are these factors interacting
in some way? Our results point to a possible crosstalk
between A2AR activity and D-serine release. First of all, at
Schaffer collateral-CA1 synapses the A2AR agonist failed to
increase NMDA-fEPSPs when the NMDA glycine site was
partially blocked by DCKA, indicating an extracellular
modulation (via D-serine binding) of NMDAR mediated by
the activation of A2AR. It is unlikely that the partial block of
the NMDAR extracellular site could mask a possible A2AR-
mediated intracellular modulation of the receptor [63],
the latter actually occurring at hippocampal mossy-CA3
synapse via calcium amplification signals [56]. In addition,
enzymatic degradation of D-serine by DAAO prevented the
A2AR agonist mediated potentiation of NMDA-fEPSPs,
supporting the D-serine requirement for VT7 effect.
Secondly, by means of mass spectrometry analysis, we
have shown that primary glial cells and purified microglia
are capable to release D-serine in the medium after stimu-
lation with VT7. These observations suggest a direct role of
A2AR in controlling the release of D-serine from glia that in
turn can modulate NMDAR functions. To the best of our
knowledge, this is the first report on adenosine-mediated
release of D-serine from glia. A2AR are indeed expressed on
microglia and astrocytes [49,64,65], usually coupled to Gs
proteins, enhancing PKA or PKC activity [56,58,66]. Inter-
estingly, PKC activity seems relevant in regulating SR activ-
ity and D-serine availability [67-69]. Since it has been
reported that neuronal cells can release D-serine, with
controversial functions on synaptic NMDAR [70,71], we
investigated whether VT7 stimulated D-serine release from
neurons. The basal release of D-serine from neurons
appeared markedly reduced compared to glia and the acti-
vation of neuronal A2AR was unable to further increase the
extracellular D-serine levels, although we cannot exclude
an indirect modulation of neuronal D-serine via other
mediators released by CX3CL1-activated microglia.
We have previously demonstrated that CX3CL1 inhibits
AMPA-mediated transmission and LTP expression [15,17]
while here we reported that CX3CL1 potentiates NMDAR.
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We speculate that the persistent CX3CL1-mediated po-
tentiation of NMDA function and the consequent calcium
increase could interfere with the complex mechanisms of
LTP induction that depends not only by the precise ampli-
tude but also by the duration of postsynaptic Ca2+ increase
and by the recent history of synaptic activity. Indeed, it has
been demonstrated that prior activation of NMDAR either
by synaptic or pharmacological stimulation could effectively
inhibit the subsequent LTP induction [72,73].
Since in our experimental setting we recorded synaptic
NMDAR blocking AMPAR component, it would be
informative to investigate CX3CL1-mediated NMDAR
modulation in a more physiological condition, where
neuronal and glial AMPAR are activable.
Interestingly, the effect of CX3CL1 seems to be specific
for the synaptic NMDARs that are exclusively gated by the
coagonist D-serine [23]. It has been reported that activa-
tion of synaptic NMDARs (NR2A-containing NMDARs)
preferentially triggers cell survival pathways, whereas
stimulation of the whole-cell population of NMDARs and/
or selective activation of extrasynaptic NMDARs (NR2B-
containing NMDARs) signals toxic stimuli ([74,75], but
see also [23]). Therefore, CX3CL1-mediated potentiation
of synaptic NMDAR function can possibly contribute to
the neuroprotective action of CX3CL1 described in differ-
ent in vitro and in vivo conditions [11,12,14].
Future studies are warranted to discern the role and the
precise mechanism of CX3CL1-mediated potentiation of
NMDA-fEPSPs in both physiological and pathological
condition, with particular attention to the sequence of me-
diators and cell types involved, namely neurons, astrocytes
or microglia. Nevertheless, considering overall data, we
can speculate that on microglial cells the activation of
CX3CR1 triggers the release of adenosine that in turn, via
A2AR activity, increases the release of D-serine from glia
leading to a potentiation of NMDA function (Figure 8).
Conclusions
In summary, we have demonstrated a direct association
between the effects of CX3CL1 on NMDAR activation and
increased levels of D-serine and A2AR activity within the
CA1 region of the hippocampus. The CX3CL1-CX3CR1
axis therefore represents a pathway for direct communica-














Figure 8 Suggested mechanism of CX3CL1 action. Activation of microglial CX3CR1 by exogenous application of CX3CL1 induces the release of
adenosine (1) that in turn activates adenosine receptor type A2 (A2AR) located on microglia cells and, possibly, on astrocytes stimulating the
release of D-serine (2). The binding of the cofactor D-serine to the synaptically activated N-methyl-D-aspartate receptors (NMDARs) (3) potentiates
the receptor function. Note that α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are blocked and, for clarity, only
factors demonstrated to play a role in the described mechanism are represented.
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Additional files
Additional file 1: Figure S1. Extracted ion chromatogram detected at
m/z 356.1/192.0 (Q1/Q3) which is specific for the Marfey’s derivatives
L-Ser (2,4-dinitro-phenyl-5-L-alanine amide- (DNPA-)L-Ser) and D-Ser
(DNPA-D-Ser). Note the clear resolution of Marfey’s derivative, DNPA-L-Ser
and DNPA-D-Ser.
Additional file 2: Figure S2. Extracted ion chromatogram of a blank
sample. Note the absence of peaks in modified artificial cerebrospinal fluid
(M-ACSF) that interfere with 2,4-dinitro-phenyl-5-L-alanine amide- (DNPA-)L-
Ser or DNPA-D-Ser.
Additional file 3: Figure S3. CX3CL1 does not affect afferent volley and
paired pulse facilitation (PPF). (A) Representative traces of NMDA-fEPSPs
responses in control, after 20 minutes of CX3CL1 and after 20 minutes of
wash. Note the potentiation of the NMDA-fEPSPs during chemokine
treatment without changes in the amplitude of the afferent volley. (B)
Top: representative traces of N-methyl-D-aspartate receptor component
of field excitatory postsynaptic potentials (NMDA-fEPSPs) responses
evoked by a pair of stimuli (50 ms interval) delivered to the Shaffer
collateral in control and after 20 minutes of CX3CL1 application, as
indicated (vertical scale bar: 0.2 mV, horizontal scale bar: 20 ms). Bottom:
histogram of paired-pulse ratio (PPR), expressed as the ratio of the
amplitude of the second fEPSP vs the first (n = 6/4). (C) Top:
representative traces of NMDA currents evoked by a pair of stimuli as in
(B); (cells held at 10 mV in standard artificial cerebrospinal fluid (ACSF),
vertical scale bar: 20 pA, horizontal scale bar: 20 ms). Bottom: histogram
of paired-pulse ratio (PPR) expressed as the ratio of the peak amplitude
of the second response vs the first (n = 5/5). Note no difference in PPR
before and after CX3CL1 application. Bars: mean ± SEM, CX3CL1 (5 nM).
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